From a recent study, it was found that nonablative Er:YAG laser treatment is capable of treating chronic prostatitis. More studies are required to verify if it’s safe and effective.

In this study, the laser group was given two sessions of Erbium:YAG laser through intraurethral route in a long, nonablative train of long pulses. They were applied at the male prostatic urethra level. The tadalafil group was given the oral tadalafil (5 mg per day), for two months successively.

The efficiency was evaluated with the help of maximum urethral flow, International Prostate Symptom Score (IPSS) questionnaire and visual analogue scale pain score, and at up to 12 months of follow-up visits following starting the therapy. Adverse effects were verified after every therapy and follow-up sessions.

The outcomes demonstrated a considerable reduction in the IPSS score in both groups on the follow-up of up to the 12-month.

In both the groups, the reduction in the VAS pain score was also considerable. In the tadalafil group, it was lasting up to 3 months, and in laser group, it was lasting up to 6 months.

It was concluded that the nonablative Er:YAG laser is a potential treatment for chronic prostatitis.